Premium
Longitudinal non‐adherence predicts treatment escalation in paediatric ulcerative colitis
Author(s) -
Carmody Julia K.,
Plevinsky Jill,
Peugh James L.,
Denson Lee A.,
Hyams Jeffrey S.,
Lobato Debra,
LeLeiko Neal S.,
Hommel Kevin A.
Publication year - 2019
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.15445
Subject(s) - mesalazine , medicine , ulcerative colitis , prospective cohort study , pill , longitudinal study , inflammatory bowel disease , disease , pharmacology , pathology
Summary Background Medication non‐adherence in paediatric ulcerative colitis (UC) has been associated with negative health outcomes including flares in disease activity. However, no studies to date have examined longitudinal adherence to maintenance medication in a prospective controlled trial. Aims To determine whether objectively measured adherence to standardised mesalazine (mesalamine) therapy over time was related to remission at 52 weeks and the need for treatment escalation in newly diagnosed paediatric patients with UC Methods PROTECT (NCT01536535) was a prospective, inception cohort, multi‐site study of paediatric patients aged 4‐17 years with newly diagnosed UC followed for 52 weeks. Patients received standardised mesalazine, with pre‐established criteria for escalation to thiopurines or anti‐TNFα inhibitors. Patients used pill bottles with electronic caps to monitor mesalazine adherence. We tested whether longitudinal adherence to mesalazine predicted steroid‐free remission at week 52 ( i.e. quiescent disease on mesalazine alone with no corticosteroids ≥4 weeks prior) and need for treatment escalation ( i.e. introduction of immunomodulators, calcineurin‐inhibitors or anti‐TNFα inhibitors). Results Among 268 patients, average mesalazine adherence trajectories did not predict week 52 steroid‐free remission. Declining adherence over time strongly predicted treatment escalation ( β = −.037, P = .001). By month 6, adherence rate ≤85.7% was associated with treatment escalation. Conclusions Non‐adherence may have affected therapeutic efficacy of standardised mesalazine, thereby contributing to need for treatment escalation. Routine adherence monitoring for at least 6 months following treatment initiation and addressing adherence difficulties early in the disease course are recommended.